CLAIMS

1. Use of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for preventing, reducing or treating emotional blunting in a patient.

2. The use according to claim 1, wherein said patient is suffering from a CNS disease or disorder.

3. The use according to claim 1 or 2, wherein said patient experiences emotional blunting as part of a CNS disease or disorder.

4. The use according to any one of claims 2-3, wherein said CNS disease or disorder is selected from psychiatric disorders, such as, psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, catatonia, delusional disorder; mood disorders, such as bipolar disorder, cyclothymic disorder, major depression, dysthymia, premenstrual dysphoric disorder and substance use disorders.

5. The use according to claim 1, wherein said patient has a history of signs and symptoms of emotional blunting resulting from an administration of a medicament, and

   wherein said medicament resulting in signs and symptoms of emotional blunting in said patient is not 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof.

6. The use according to claim 5, wherein said medicament is provided for the treatment of one or more CNS disease or disorder, and wherein said CNS disease or disorder is selected from the group consisting of: Major Depressive Disorder (MDD), Major Depressive Episode (MDE), Post Traumatic Stress Disease (PTSD), schizophrenia, cognitive impairment, Parkinson's disease, autism, vascular dementia and multiple system atrophy.

7. The use according to claim 1, wherein said emotional blunting is seen in connection with administration of an adequate dose of a medicament for the treatment of one or more CNS diseases or disorders, wherein said one or more CNS diseases or disorders is optionally selected from the group of psychotic disorders, such as schizophrenia, schizoaffective disorder, schizophreniform disorder, catatonia, delusional disorder; mood disorders, such as bipolar disorder, cyclothymic disorder, major depression, dysthymia, premenstrual dysphoric disorder and substance use disorders,

   wherein said medicament is not 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof and

   wherein said adequate dose of said medicament is a dose as described in said medicaments label.

8. The use according to any one of the claims 5-7, wherein said medicament is to be administered for the prevention or treatment of one or more CNS diseases or disorder, or signs and symptoms thereof and wherein said medicament is not 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof, wherein said emotional blunting is

   1) a result of said CNS disease or disorder,

   2) a result of inadequate response to said medical treatment or

   3) reported as being caused by of an inadequate response of a medical treatment of a CNS disease or disorder.

9. The use according to any one of claims 2-4, 6-8, wherein said CNS disease or disorder is selected from Major Depressive Disorder (MDD) and schizophrenia.

10. The use according to any one of claims 5-8 , wherein said medicament is a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI).

11. The use according to claim 10, wherein said medicament is selected from Escitalopram, Fluoxetine, Paroxetine, Sertraline, Venlafaxine, Desvenlafaxine and Duloxetine.

12. The use according to any one of claims 1-11, wherein said patient has a total score of above 30 in an Oxford Depression Questionnaire (ODQ).

13. The use according to any one of claims 1-12, wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrobromide salt, lactic acid salt and pyroglutamate salt.

14. The use according to claim 13, wherein said pharmaceutically acceptable salt is selected from the hydrobromide (α) salt, hydrobromide (β) salt and hydrobromide (γ) salt.

15. The use according to any one of the preceding claims 1-14, wherein 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof is to be administered in a unit dose of 5mg, 10mg or 20mg 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

16. The use according to any one of the preceding claims 1-15, wherein 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof is to be administered in a dose of 5 mg/day, 10mg/day or 20mg/day of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

17. The use according to any one of the preceding claims 1-16, wherein 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof is to be administered as oral tablets or oral drops.